ARLO vs DLX

ARLO exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess bankruptcy risk. While the company shows strong recent earnings growth and beats on earnings surprises, profitability remains thin with negative ROA and elevated valuation multiples. The stock trades significantly above its Graham Number of $0.91 and intrinsic value of $0.21, suggesting substantial premium pricing. Analysts maintain a strong_buy recommendation, but insider selling worth $17.9M over the past six months raises caution, offsetting bullish sentiment.

DLX presents a conflicting profile: a stable Piotroski F-Score of 4/9 and a strong history of earnings beats, contrasted by a current price ($30.33) that significantly exceeds both its Graham Number ($24.75) and Intrinsic Value ($12.60). While the Forward P/E of 7.06 and PEG of 0.62 suggest future value, the current financial health is strained by a high Debt/Equity ratio (2.22) and poor liquidity (Quick Ratio 0.40). The stock has experienced a massive 1-year run-up (+108.4%) that is not supported by current revenue growth (2.8%) or earnings growth (-7%).